NEW YORK, Sept. 27, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between March 29, 2024 and June 27, 2025, both dates inclusive (the “Class Period”), of the important October 14, 2025 lead plaintiff deadline. SO WHAT: If you purchased Unicycive securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee ar ...

In the past week or so, some initial public offerings prompted big insider buying. ...

Onconetix (ONCO) announced the September 22, 2025 signing and closing of a private placement of shares of the Company’s Series D Convertible Preferred Stock, $0.00001 par value, and warrants to purchase up to an aggregate of 4,362,827 shares of the Company’s common stock, $0.00001 par value per share, for an aggregate purchase price of approximately $12.9 million. Approximately $9.3 million was paid in cash and the balance was used to offset certain amounts owed by the Company to certain investors. The Ser ...

Key TakeawaysAmgen (AMGN) announced a $650 million expansion of its U.S. manufacturing network in Puerto Rico, a strategic response to President Trump's impending 100% tariff on pharmaceutical products not manufactured domestically, creating approximately 750 jobs.Starbucks (SBUX) is set to close 434 North American stores by the end of September, reducing its footprint from 18,734 to 18,300 locations, and laying off 900 non-retail employees as part of a broader turnaround strategy.China's industrial profits ...

NEW YORK, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced that it will host a conference call and live webcast at 8:30 am ET on September 29, 2025, to discuss recently announced updated overall survival and safety data in first-line pancreatic cancer patients treated with atebimetinib + mGnP (N=34) with 9 months median follow up. “These exciting results were first announced in our press rel ...

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced the company will hold a conference call and webcast on Monday, September 29 at 8:30 a.m. ET to share topline results from RSVHR, a Phase 2b study evaluating zelicapavir for the treatment of respiratory syncytial virus (RSV) in high-risk adults. Conference Call and Webcast. ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Tarsus Pharmaceuticals (NASDAQ: TARS ) is now two years into the launch of Xdemvy (lotilaner) for Demodex blepharitis, and while sales have passed $100M per quarter, so has SG&A. In May, I rated TARS a buy, noting their "Get Big Fast" approachScientist and trader of biotech stock. Focus on trading around events such as trial results and NDA/BLA approvals. Also covering companies in industries regulated by the FDA. Articles present my opinion on stocks, but don't constitute investment advice.Analyst’s Disclo ...

Tarsus Pharmaceuticals (NASDAQ: TARS ) is now two years into the launch of Xdemvy (lotilaner) for Demodex blepharitis, and while sales have passed $100M per quarter, so has SG&A. In May, I rated TARS a buy, noting their "Get Big Fast" approachScientist and trader of biotech stock. Focus on trading around events such as trial results and NDA/BLA approvals. Also covering companies in industries regulated by the FDA. Articles present my opinion on stocks, but don't constitute investment advice.Analyst’s Disclo ...

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming November 18, 2025 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Jasper Therapeutics, Inc. ("Jasper†or the "Company†) (NASDAQ: JSPR) securities between November 30, 2023 and July 3, 2025, inclusive (the "Class Period†). IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN JASPER THERAPEUTICS, INC. (JSPR), CONTACT THE LAW OFFICES OF HOWARD G. SMITH TO PARTIC. ...